SYBX - Synlogic, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.18
-0.12 (-1.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.30
Open8.19
Bid7.02 x 1000
Ask9.94 x 900
Day's Range8.06 - 8.21
52 Week Range5.75 - 14.59
Volume20,197
Avg. Volume60,925
Market Cap207.679M
Beta (3Y Monthly)2.57
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire10 days ago

    Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update

    – Company will host a conference call and webcast at 5:00 pm ET today –

  • Business Wire17 days ago

    Synlogic Announces First Quarter 2019 Conference Call and Webcast

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2019 financial results after the market closes on Thursday, May 9, 2019. The press release will be followed by a conference call at 5:00 pm ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.

  • Business Wire19 days ago

    Synlogic Presents Data Describing a Solid Oral Formulation Process for Synthetic Biotic™ Medicine SYNB1618 for the Treatment of PKU at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

    Synlogic, Inc., (SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced that data demonstrating its development of a robust and reproducible process to generate a solid oral formulation of its Synthetic Biotic medicine, SYNB1618, are being presented today at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). Synlogic is developing SYNB1618 for the treatment of phenylketonuria (PKU).

  • Business Wirelast month

    Synlogic to Present Data from New Solid Oral Formulation Process at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

    Synlogic, Inc., (SYBX) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that data from its program to develop solid oral formulations of its Synthetic BioticTM medicines will be presented at the upcoming 22nd Annual Meeting of the American Society of Gene & Cell Therapy, which is being held from April 29 to May 2, 2019, in Washington, DC. The presentation will focus on preparation and characteristics of a solid oral preparation of SYNB1618, Synlogic’s synthetic biotic medicine for the treatment of phenylketonuria (PKU). Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.

  • Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer
    Business Wirelast month

    Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer

    Synlogic, Inc. (SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Scott Plevy, M.D., as Chief Scientific Officer. Dr. Plevy will have responsibility for Synlogic’s research organization and will report to Aoife Brennan, M.B., Ch.B., Synlogic’s president and chief executive officer.

  • Business Wire2 months ago

    Synlogic to Webcast Presentation at the 18th Annual Needham Healthcare Conference

    Synlogic (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 18th Annual Needham Healthcare Conference at 3:30 pm ET on Tuesday, April 9, 2019, in New York City. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer beneficial microbes to perform or deliver critical functions missing or damaged due to disease.

  • Business Wire2 months ago

    Synlogic to Webcast Presentation at the Oppenheimer 29th Annual Healthcare Conference

    Synlogic (SYBX) announced today that Caroline Kurtz, Ph.D., Synlogic’s Head of Metabolism, will provide a corporate update at Oppenheimer’s 29th Annual Healthcare Conference at 3:20 pm ET on Wednesday, March 20, 2019, in New York City. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer beneficial microbes to perform or deliver critical functions missing or damaged due to disease.

  • Business Wire2 months ago

    Synlogic Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    – Ended 2018 with approximately $123 million in cash and investments, which provides runway through 2020 –

  • Business Wire2 months ago

    Synlogic Announces Achievement of Milestone in Collaboration to Develop Synthetic Biotic™ Medicines to Treat Inflammatory Bowel Disease

    Synlogic, Inc., (SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the advancement of Synthetic Biotic medicines to the lead optimization stage in its collaboration with AbbVie, a global biopharmaceutical company, to develop an oral treatment for inflammatory bowel disease (IBD). "Synlogic is a leader in the use of synthetic biology for the development of novel bacterial therapeutics," said, Lisa Olson Ph.D., Vice President, Immunology Research, AbbVie.

  • Business Wire2 months ago

    Synlogic Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, announced today that the Company will release its fourth quarter and full year 2018 financial results before the market opens on Tuesday, March 12, 2019. During the conference call, the Company will review its financial results and provide a corporate update. The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers.

  • Business Wire3 months ago

    Synlogic to Present at Investor Conferences in March

    Cowen and Company 39th Annual Health Care Conference at 11:20 am ET, on Monday, March 11, 2019, in Boston. Live webcasts of the presentations can be accessed under “Event Calendar” in the Investors & Media section of the Company’s website. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.

  • Business Wire3 months ago

    Synlogic to Webcast Presentation at the SVB Leerink 8th Annual Global Healthcare Conference

    Synlogic (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the SVB Leerink 8th Annual Global Healthcare Conference at 1:30 pm ET on Thursday, February 28, 2019, in New York City. A live webcast of the presentation can be accessed under “Event Calendar” in the Investors & Media section of the Company’s website. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.

  • Synlogic Appoints Patricia N. Hurter, Ph.D. to Board of Directors
    Business Wire3 months ago

    Synlogic Appoints Patricia N. Hurter, Ph.D. to Board of Directors

    Synlogic, Inc., (SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Patricia N. Hurter, Ph.D., Senior Vice President of Pharmaceutical and Preclinical Sciences at Vertex Pharmaceuticals, Inc., to its board of directors. “I am delighted to welcome Trish to our Board,” said Aoife Brennan, M.B., Ch.B., Synlogic’s president and chief executive officer.

  • Business Wire4 months ago

    Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogic’s Synthetic Biotic™ Medicine in Development as a Potential Treatment for Hyperammonemia

    Synlogic, Inc., (SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the publication in Science Translational Medicine of clinical data from its Phase 1 clinical study in healthy volunteers and supporting preclinical data from its investigational Synthetic Biotic candidate, SYNB1020. The data support the continued development of SYNB1020 which is currently being evaluated in a Phase 1b/2a clinical trial in patients with cirrhosis and elevated blood ammonia.

  • Business Wire4 months ago

    Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2019 Catalysts

    Synlogic, Inc. (SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial microbes to develop novel living medicines, today provided an overview of recent progress and outlined key objectives and anticipated milestones for 2019. “2018 was a significant year for Synlogic as we advanced our two lead clinical programs and platform. In addition, we broadened our pipeline with the addition of our first immuno-oncology development candidate, SYNB1891,” said Aoife Brennan, M.B. Ch.B., Synlogic’s president and chief executive officer.

  • Business Wire5 months ago

    Synlogic Expands Capabilities in Manufacturing with the Appointment of Head of Technical Operations and Establishment of In-house Production of Clinical Trial Material for its Synthetic BioticTM Medicines

    Synlogic, Inc. (SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial microbes to develop novel living medicines, today announced the appointment of Antoine Awad as Head of Technical Operations, and the expansion of its manufacturing capabilities to produce clinical trial material for mid-stage studies of its oral and immuno-oncology programs, through entry into an agreement to lease GMP clean-room space from the Azzur Group, LLC. “We are delighted to welcome Tony to Synlogic at this critical stage in the Company’s development as we expand our manufacturing capabilities enabling the production of high-quality, clinical trial material in-house,” said Aoife Brennan, M.B., Ch.

  • GlobeNewswire6 months ago

    Research Report Identifies Synlogic, Consolidated Water Co., AeroCentury, Tecogen, Truett-Hurst, and Marchex with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire6 months ago

    Synlogic to Webcast Presentation at the 30th Annual Piper Jaffray Healthcare Conference

    Synlogic (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 30th Annual Piper Jaffray Healthcare Conference at 8:30 am ET on Wednesday, November 28, 2018, in New York City. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer beneficial microbes to perform or deliver critical functions missing or damaged due to disease.

  • Business Wire6 months ago

    Synlogic Reports Third Quarter 2018 Financial Results and Provides Program Updates

    – Advancement of SYNB1891, the first Synthetic Biotic™ immuno-oncology candidate to enable Investigational New Drug Application filing in 2H 2019 –

  • Business Wire6 months ago

    Synlogic Presents Data at the 2018 Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)

    Synlogic, Inc. (SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial microbes to develop novel living medicines, today announced the presentation of data from a cross-sectional study on ammonia levels in patients with cirrhosis and healthy volunteers, and preclinical studies of its Synthetic Biotic strains in rodent models of liver failure. The presentations were made at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Disease (AASLD), which is being held in San Francisco, November 9 to 13, 2018. “Hepatic Encephalopathy is a major cause of morbidity and mortality in patients with chronic liver disease.

  • Business Wire6 months ago

    Synlogic Announces Third Quarter 2018 Conference Call and Webcast

    Synlogic, Inc. (Nasdaq: SYBX), announced today that the Company will release its third quarter 2018 financial results after the market closes on Tuesday, November 13, 2018. The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.

  • Business Wire6 months ago

    Synlogic Presents Preclinical Data from First Synthetic BioticTM Clinical Candidate in Immuno-Oncology at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

    Synlogic, Inc. (SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial microbes to develop novel living medicines, today announced the presentation of preclinical data from its first immuno-oncology (IO) program at the 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). Synlogic’s first Synthetic Biotic clinical candidate (SYNB1891) is designed to induce the production of type I interferon (IFN) through dual activation of innate immune pathways. Data that will be presented at SITC 2018 demonstrate that SYNB1891 generated significant anti-tumor activity, systemic immunity and long-term immunological memory in mouse tumor models.

  • Business Wire7 months ago

    Synlogic to Host Analyst & Investor Event at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced that the Company will host an event for analysts and investors in conjunction with the Society for Immunotherapy of Cancer’s 33rd Annual Meeting * Pre-Conference Programs (SITC 2018), with formal presentations beginning at 12:30 pm ET on November 10, 2018. At SITC 2018, Synlogic will deliver a poster presentation of preclinical data for its innate immune activator candidate.

  • Business Wire8 months ago

    Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer

    Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the appointment of Aoife Brennan, M.B., B.Ch., as president and chief executive officer of Synlogic, effective immediately. Dr. Brennan joined Synlogic as chief medical officer in 2016 and has served as interim president and chief executive officer since May 2018. “After conducting a thorough search process, it was clear to the board of directors that Aoife is the right person to lead Synlogic at this time in the company’s evolution,” said Peter Barrett, chairman of Synlogic’s board of directors.

  • Business Wire8 months ago

    Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology

    Synlogic (SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the Leerink Partners Roundtable Series on Rare Diseases and Oncology at 11:30 am ET on Tuesday, October 2, 2018, in New York City. Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform.